

Ablexis Media Contact:

Pure Communications, Inc.

Kristie Wallis, (336) 774-8666

kristie@purecommunicationsinc.com

Ablexis Announces Licensing of the AlivaMab Mouse Technology to Another Major Pharmaceutical Company

Non-Exclusive License Provides Access to Novel Transgenic Mouse Platform for the Discovery of Antibody Therapeutics and Further Validates Potential of the Technology

San Francisco – July 10, 2012 – [Ablexis](#), LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative platform for discovery of the next generation of breakthrough antibody drugs, today announced another non-exclusive license agreement with a top 20 global pharmaceutical company. This announced agreement follows the announcement in 2010 of the Ablexis pharma consortium, non-exclusive licensing agreements with five of the top 20 global pharmaceutical companies.

This latest non-exclusive licensing of the AlivaMab Mouse platform demonstrates the continued demand for the Ablexis technology by leading antibody drug discovery organizations. The license enables the pharmaceutical company to deploy the technology broadly throughout its organization and provides for long-term access. Under the terms of the agreement, the licensee is required to make a seven-figure pre-delivery payment and an eight-figure post-delivery payment in return for long-term non-exclusive rights to utilize the technology broadly for therapeutic antibody discovery.

“We are delighted to welcome a new licensee to the group of leading pharmaceutical companies that have recognized the best-in-class design of the AlivaMab Mouse Platform for therapeutic antibody discovery,” said Larry L. Green, Ph.D., chief executive officer of Ablexis. “The Ablexis team, with its unparalleled experience in the successful creation, use and commercialization of transgenic antibody discovery platforms, remains dedicated to making the AlivaMab Mouse platform broadly available for antibody drug discovery through flexible partnering strategies. Ablexis looks forward to establishing additional partnerships to satisfy the biopharmaceutical industry’s need for robust antibody drug discovery platforms.”

About Ablexis, LLC

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, was founded in December 2009, based on technology principles established by its subsidiary, Aliva Biopharmaceuticals, Inc. Ablexis is developing the

AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. In 2010 Ablexis closed the Ablexis Consortium in which five of the top 20 global pharmaceutical companies licensed the AlivaMab Mouse technology. Ablexis is continuing the commercialization of the AlivaMab Mouse technology through non-exclusive licenses granting broad use of the platform for discovery with no target or field-of-use restrictions. The company is based in San Francisco; more information can be found by visiting the company's website at www.ablexis.com.

###